Quantum Genomics SA
PAR:ALQGC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Quantum Genomics SA
PAR:ALQGC
|
FR |
|
S
|
Sincere Watch (Hong Kong) Ltd
HKEX:444
|
HK |
|
HAKI Safety AB
STO:HAKI B
|
SE |
Quantum Genomics SA
Quantum Genomics SA is a biopharmaceutical company, which develops new medication class for cardiovascular disease, such as high blood pressure and heart failure. The company is headquartered in Paris, Ile-De-France and currently employs 7 full-time employees. The company went IPO on 2009-07-28. The firm provides biotechnological and medical research. Its main activity is research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors). Quantum Genomics SA's activities are oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
Quantum Genomics SA is a biopharmaceutical company, which develops new medication class for cardiovascular disease, such as high blood pressure and heart failure. The company is headquartered in Paris, Ile-De-France and currently employs 7 full-time employees. The company went IPO on 2009-07-28. The firm provides biotechnological and medical research. Its main activity is research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors). Quantum Genomics SA's activities are oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
